The prognostic impact of Claudin 6 in papillary renal cell carcinoma

Mikuteit M, Zschäbitz S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Steffens S, Erlmeier F (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 231

Article Number: 153802

DOI: 10.1016/j.prp.2022.153802

Abstract

Background: Claudins are promising biomarkers for diagnosis and prognosis or targets for treatment. They play a major role in signal transduction and are important in nearly all aspects of tumorigenesis. Claudin 6 is a member of the claudin family and is part of the tight junction molecule. It is reactivated in several cancer types and serves as prognostic marker in, for example, gastric, breast or non small cell lung cancer. The prognostic role of Claudin 6 in renal cell carcinoma (RCC), especially in papillary RCC (pRCC), is still unclear. Patients and Methods: The patients’ sample collection was a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of Claudin 6 was determined by immunohistochemistry. Results: In total, Claudin 6 staining was positive in 55 of 240 type 1 and 30 of 128 type 2 pRCC cases. Kaplan-Meier analysis disclosed an overall survival of 84% for Claudin 6- compared to 78% for Claudin 6 + in pRCC type 1 tumors (p = 0.449, log-rank) and 68% for Claudin 6- compared to 65.4% for Claudin 6 + in pRCC type 2 tumors (p = 0.364, log-rank). Conclusion: In this study, claudin 6 expression showed no significant association regarding overall survival (OS) and therefore did not qualify as a prognostic marker in pRCC. Future studies will have to determine, whether Claudin 6 plays a prognostic role in other RCC entities. In addition, the function of Claudin 6 as a predictive marker for therapeutic approaches has to be evaluated in future studies.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Münster Germany (DE) Universitätsklinikum Göttingen Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Universitätsklinikum des Saarlandes (UKS) Germany (DE) Klinikum der Universität München Germany (DE) Universitätsklinikum Regensburg Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) Germany (DE) St. Elisabeth Gruppe GmbH - Katholische Kliniken Rhein-Ruhr Germany (DE)

How to cite

APA:

Mikuteit, M., Zschäbitz, S., Stöhr, C., Herrmann, E., Polifka, I., Agaimy, A.,... Erlmeier, F. (2022). The prognostic impact of Claudin 6 in papillary renal cell carcinoma. Pathology Research and Practice, 231. https://doi.org/10.1016/j.prp.2022.153802

MLA:

Mikuteit, Marie, et al. "The prognostic impact of Claudin 6 in papillary renal cell carcinoma." Pathology Research and Practice 231 (2022).

BibTeX: Download